Chemfab Alkalis Board Approves FY26 Financial Results and Recommends Final Dividend
Chemfab Alkalis Limited's Board approved FY26 audited standalone and consolidated financial results. A final dividend of ₹1.25 per share was recommended. M/s. Madhavan, Mohan & Associates and M/s. Brahmayya & Co. were reappointed as cost and internal auditors, respectively, for FY27. The company also confirmed it is not a large corporate.
The approval of financial results and recommendation of dividend are material events for shareholders. The reappointment of auditors and the confirmation of not being a large corporate also provide clarity on the company's regulatory status and operational stability.
The company is recommending a dividend and approving financial results, which are generally positive indicators for shareholders. The reappointment of auditors also signifies stability.
Chemfab Alkalis Limited's Board of Directors, in a meeting held on May 13, 2026, approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The Board also recommended a final dividend of ₹1.25 per share for approval by shareholders at the upcoming Annual General Meeting.
Furthermore, the Board approved the reappointment of M/s. Madhavan, Mohan & Associates as the cost auditor and M/s. Brahmayya & Co. as the internal auditors for the financial year 2026-2027. The meeting commenced at 2:00 PM and concluded at 7:00 PM.
In a separate disclosure, Chemfab Alkalis Limited confirmed that it is "Not a Large Corporate" as per the applicability criteria of the SEBI Operational Circular dated August 10, 2021, as amended. As of March 31, 2026, the company's outstanding borrowings were ₹8,143 Lakhs. The company's highest credit rating during the previous financial year was IND BBB+/Negative/IND A2 from ICRA.
What to do with a filing like this
Chemfab Alkalis Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Chemfab Alkalis Limited. Read the original for the full detail.